HOTH — Hoth Therapeutics Share Price
0.000.00%
Last trade - 00:00- $4.02m
- -$3.54m
- 14
- 49
- 31
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.58 | ||
| Price to Tang. Book | 0.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -96.2% | ||
| Return on Equity | -78.21% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.
Directors
- Robb Knie PRE (52)
- David Briones CFO (44)
- Stefanie Johns CSO (36)
- Jane Springer VPR
- Wayne Linsley IND (64)
- David Sarnoff IND (53)
- Graig Springer IND (41)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 16th, 2017
- Public Since
- February 15th, 2019
- No. of Shareholders
- 101
- No. of Employees
- 2
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 4,888,804
- Address
- 590 Madison Avenue, 21St Floor, NEW YORK, 10022
- Web
- https://hoththerapeutics.com/
- Phone
- +1 6467562997
- Auditors
- WithumSmith Brown PC
Upcoming Events for HOTH
Q2 2024 Hoth Therapeutics Inc Earnings Release
Hoth Therapeutics Inc Annual Shareholders Meeting
Q3 2024 Hoth Therapeutics Inc Earnings Release
Similar to HOTH
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Hoth Therapeutics share price?
As of Today at 21:10 UTC, shares in Hoth Therapeutics are trading at $0.92. This share price information is delayed by 15 minutes.
How has the Hoth Therapeutics share price performed this year?
Shares in Hoth Therapeutics last closed at $0.92 and the price had moved by -69.3% over the past 365 days. In terms of relative price strength the Hoth Therapeutics share price has underperformed the S&P500 Index by -75.57% over the past year.
What are the analyst and broker recommendations for Hoth Therapeutics?
The overall consensus recommendation for Hoth Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Hoth Therapeutics dividend yield?
Hoth Therapeutics does not currently pay a dividend.
Does Hoth Therapeutics pay a dividend?
Hoth Therapeutics does not currently pay a dividend.
When does Hoth Therapeutics next pay dividends?
Hoth Therapeutics does not currently pay a dividend.
How do I buy Hoth Therapeutics shares?
To buy shares in Hoth Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hoth Therapeutics?
As of the previous close price of $0.92, shares in Hoth Therapeutics had a market capitalisation of $4.52m.
Where are Hoth Therapeutics shares listed?
Here are the trading details for Hoth Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: HOTH
What kind of share is Hoth Therapeutics?
Based on an overall assessment of its quality, value and momentum Hoth Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hoth Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Hoth Therapeutics is $4.67. That is 405.41% above the last closing price of $0.92.
Analysts covering Hoth Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.78 for the next financial year.
What is the trend in the Hoth Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hoth Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -40.2%.
As of the last closing price of $0.92, shares in Hoth Therapeutics were trading -29.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hoth Therapeutics PE Ratio?
The Hoth Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hoth Therapeutics?
Hoth Therapeutics' management team is headed by:
- Robb Knie - PRE
- David Briones - CFO
- Stefanie Johns - CSO
- Jane Springer - VPR
- Wayne Linsley - IND
- David Sarnoff - IND
- Graig Springer - IND